Sanofi annual report, Q4 FY2019

Sanofi 2019 Form 20-F Summary

Business context and reporting period

Sanofi is a France-based global healthcare company operating in Pharmaceuticals, Consumer Healthcare and Vaccines. This Form 20-F reports the fiscal year ended December 31, 2019, under IFRS. Although the request refers to 2019 Q4, the filing is an annual report and the supplied text does not provide a clear standalone fourth-quarter income statement or cash flow.

Key financial metrics

Net debt is a non-GAAP measure and, following adoption of IFRS 16, excludes lease liabilities. Year-end lease liabilities were €1.248 billion. Sanofi also had €8 billion of undrawn confirmed credit facilities, with no financial-ratio covenants. The proposed 2019 dividend was €3.15 per share, subject to shareholder approval, equal to 52.6% of business net income.

Material changes versus the prior comparable period

• Reported sales growth was supported by exchange rates; CER growth was 2.8%, or 3.6% on a constant-exchange-rate and constant-structure basis.
• Pharmaceuticals sales were €25.708 billion (+4.1% reported; +2.2% CER); Vaccines €5.731 billion (+12.0%; +9.3% CER); and Consumer Healthcare €4.687 billion (+0.6%; -0.8% CER).
• Specialty Care and Vaccines were key growth contributors. Dupixent sales rose 151.6% CER to €2.074 billion. Emerging Markets sales increased 8.7% CER.
• Pressure on mature products offset growth: Diabetes sales fell 8.2% CER, Established Prescription Products fell 8.3% CER, and Lantus sales declined 17.0% CER to €3.012 billion. Sanofi estimated €912 million of reported sales erosion from generic and biosimilar competition.
• Operating income and IFRS net income declined sharply, primarily reflecting €3.604 billion of intangible-asset impairment losses, compared with €718 million in 2018. Business net income, which excludes specified items, increased.
• Operating cash flow improved and net debt fell, largely reflecting cash generated by operations. Investing cash outflow was €1.212 billion versus €12.866 billion in 2018, when Bioverativ and Ablynx acquisitions drove investment spending.

Outlook, management commentary, risks and unusual items

• CEO Paul Hudson’s December 2019 strategy emphasized growth, innovation, efficiency and a new operating model. Sanofi targeted €2 billion of savings by 2022 to fund growth and support expansion of its business operating income margin. The filing does not provide a clear consolidated 2020 financial guidance figure in the supplied text.
• Sanofi prioritized six potentially transformative therapies, with planned submission dates starting in 2021, and discontinued research in diabetes and cardiovascular disease. It said it would complete ongoing efpeglenatide studies while seeking a partner to assume commercialization.
• Risks include pricing and reimbursement pressure, generic and biosimilar competition, patent challenges, dependence on key products and collaborators, product liability and regulatory proceedings, manufacturing and supply interruptions, foreign-exchange exposure, customer credit risk, and environmental obligations.
• Sanofi voluntarily recalled US and Canadian OTC Zantac in October 2019 after concerns about possible NDMA contamination. The recall contributed to a €352 million impairment of Zantac-related rights. A €2.803 billion impairment was recorded against Eloctate franchise assets following revised sales expectations amid hemophilia competition; total intangible impairment was €3.604 billion.
• China’s national volume-based procurement tender led to substantial price adjustments. Sanofi expected 2020 China sales of Plavix and the Aprovel family to be about 50% lower. It also expected significant pressure on Amaryl in China and a contraction in US Admelog sales after a 44% wholesale-price reduction.
• COVID-19 was identified as a potential supply, operating and market risk; the filing did not quantify its impact. Sanofi also disclosed a February 2020 Zantac-related indemnity arbitration initiated by Boehringer Ingelheim, which Sanofi disputed.
• Other significant exposures include €1.334 billion of provisions for product liability, litigation and other risks, €737 million for environmental risks, and €1.031 billion of uncertain income-tax liabilities. These estimates and outcomes remain subject to uncertainty.
• Post-year-end items included completion of the Synthorx acquisition on January 23, 2020, for approximately $2.5 billion, and FDA approval of Sarclisa on March 2, 2020. The auditors issued an unqualified opinion on the financial statements and internal controls; key audit matters included intangible-asset recoverability, US rebate estimates, litigation provisions and uncertain tax positions.

Important facts for investors to verify

• Reconcile IFRS earnings with business net income, including the assumptions and sensitivity behind the Eloctate impairment and other excluded items.
• Track sales, market access and pricing for Dupixent, Vaccines, Lantus, Eloctate, Plavix, Aprovel, Zantac and other products facing competition or tender pressure.
• Assess execution of the €2 billion savings target, the pipeline milestones and the new business-unit structure.
• Review cash generation, working-capital trends, debt maturities and liquidity, noting that reported net debt excludes lease liabilities.
• Monitor Zantac-related claims and indemnity disputes, other material litigation, environmental provisions and uncertain tax exposures.
• Confirm the 2019 dividend approval and payment; it was proposed, not yet approved, in this filing.